INVA
Innoviva, Inc.
NASDAQ · Healthcare · Biotechnology · US
$21.08
+1.44%Year over year
Reported trailing growth
- Revenue
- +19.8%
- EBITDA
- +590.9%
- EBIT
- +5903.5%
- EPS
- +699.1%
- Free cash flow
- -4.1%
- Operating cash flow
- -4.5%
Forward estimates
Based on analyst estimates
- Revenue
- +8.4%
- EBITDA
- -65.1%
- EPS
- -55.1%
Three-year CAGR
- Revenue
- +8.7%
- EBITDA
- +6.0%
- EBIT
- -7.5%
- Net income
- +8.2%
- EPS
- +9.4%
- Free cash flow
- -2.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026